Abstract
In recent years, the Cannabis plant (Cannabis sativa L.) has been rediscovered as a source of new medicines around the world. Despite the fact that a number of registered medicines have been developed on the basis of purified cannabis components, there is a rapid increasing acceptance and use of cannabis in its herbal form. Licensed producers of high quality cannabis plants now operate in various countries including The Netherlands, Canada, Israel, and Australia, and in many US states. The legal availability of cannabis flowers allows to prescribe and prepare different cannabis galenic preparations by pharmacists. It is believed that synergy between cannabis components, known as “entourage effect”, may be responsible for the superior effects of using herbal cannabis versus isolated compounds. So far, only a few cannabis components have been properly characterized for their therapeutic potential, making it unclear which of the isolated compounds should be further developed into registered medicines. Until such products become available, simple and accessible galenic preparations from the cannabis plant could play an important role. In cannabis, phytochemical and pharmacological attention has been attributed mainly to four major cannabinoids (Δ9- tetrahydrocannabinol, cannabidiol, cannabigerol and cannabichromene) and to terpene components. This means a basic knowledge of these compounds and their bioavailability in different administration forms is useful for producers as well as prescribers of galenic preparations. This work will outline the most important aspects of cannabinoids and terpenes, and their behaviors during preparation and use of various administration forms including vaporizing, cannabis oils and extracts, tea, and skin creams.
Keywords: Medicinal cannabis, cannabinoids, terpenes, extracts, decarboxylation, galenic preparations.
Graphical Abstract
[1]
McKim, W.A. Drugs and Behavior. An Introduction to Behavioral Pharmacology, 4th ed; Prentice-Hall: Upper Saddle River, 2000.
[2]
O’Shaugnessy, W.B. On the preparations of the Indian hemp, or gunjah (Cannabis indica): their effets on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of Medical and Physical Society of Bengal, , 1838-1840. pp. 421-461.
[3]
Robson, P. Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry, 2001, 178, 107-115.
[4]
Iversen, L.L. In: The Science of Marijuana. Chapter 4: medical uses of marijuana. ; Fact or fantasy? Oxford University Press Inc: New York, 2000; pp. 121-175.
[5]
Gaoni, Y.; Mechoulam, R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J. Am. Chem. Soc., 1971, 93(1), 217-224.
[6]
WHO (World Health Organization). 2006. Norms and Standards: Quality, Safety and Efficacy of Medicines. Available from:. http://www.who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf
[7]
GW Pharmaceuticals. 2016. Sativex® https://www.gwpharm.com/ products-pipeline/sativex-delta-9-tetrahydrocannabinol-and-cannabidiol (Accessed January 19, 2017).
[8]
Beatrice Lorenzin, Law Decree 20th March 2014, n. 36. Available from:. http://www.camera.it/_dati/leg17/lavori/stampati/pdf/ 17PDL0018760.pdf, http://www.governo.it/backoffice/allegati/75153-9310.pdf
[9]
Health Minister Decree 9th November 2015 http://www.gazzet-taufficiale.it/eli/id/2015/11/30/15A08888/sg (Accessed February 25, 2017).
[10]
SIFAP news letter, 29th September 2016. Available from: https://www.sifap.org/newsletter/sifap-propone-un-metodo-per-l-estrazione-oleosa-di-infiorescenze-femminili-di-cannabis
[11]
Citti, C.; Ciccarella, G.; Braghiroli, D.; Parenti, C.; Vandelli, M.A.; Cannazza, G. (2016). Medicinal cannabis: principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J. Pharm. Biomed. Anal., 2016, 128, 201-209.
[12]
European Medicine Agency (EMEA) ICH Topic Q2(R1) Validation of Analytical Procedures: Text and Methodology,. 2006.
[13]
Transvaal pharmacy, The Hague, The Netherlands https://www. transvaalapotheek.nl/cannabis-olie-2/ (Accessed January 2018).
[14]
Bifulco, M.; Pisanti, S. In: Medicinal use of cannabis in Europe. EMBO reports., 2015, Vol 16(Issue 2), 130-132.
[15]
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Cannabis legislation in Europe: an overview; Publications Office of the European Union: Luxembourg, 2017.
[17]
Akuutti Health Magazine,. https://yle.fi/aihe/artikkeli/2015/04/ 20/laakekannabis-edelleen-marginaalinen-laake (Accessed November 20, 2017)
[18]
Mechoulam, R.; Hanus, L.O. A historical overview of chemical research on cannabinoids. Chem. Phys. Lipids, 2000, 108(1-2), 1-13.
[19]
Mechoulam, R.; Peters, M.; Murillo-Rodriguez, E.; Hanus, L.O. Cannabidiol recent advances. Chem. Biodivers., 2007, 4(8), 1678-1692.
[20]
Bohlmann, F.; Hoffmann, E. Cannabigerol-ähnliche verbindungen aus Helichrysum umbraculigerum. In: Phytochemistry; Elsevier B.V.: Amsterdam, 1979; Vol. 18, pp. 1371-1374.
[21]
Pollastro, F.; De Petrocellis, L.; Schiano-Moriello, A.; Chianese, G.; Heyman, H.; Appendino, G.; Taglialatela-Scafati, O. Amorfrutin-type phytocannabinoids from Helichrysum umbraculigerum. Fitoterapia, 2017, 123, 13-17.
[22]
Hakeem Said, I.; Rezk, A.; Hussain, I.; Grimbs, A.; Shrestha, A.; Schepker, H.; Brix, K.; Ullrich, M.S.; Kuhnert, N. Metabolome comparison of bioactive and inactive rhododendron extracts and identification of an antibacterial cannabinoid(s) from Rhododendron collettianum. Phytochem. Anal., 2017, 28(5), 454-464.
[23]
Iwata, N.; Kitanaka, S. New cannabinoid-like chromane and chromene derivatives from Rhododendron anthopogonoides. Chem. Pharm. Bull., 2011, 59(11), 1409-1412.
[24]
Ross, S.A.; ElSohly, M.A. Constituents of Cannabis sativa L. XXVIII A review of natural constituents: 1980-1994. Zagazig J. Pharm. Sci., 1995, 4(2), 1-10.
[25]
Turner, C.E.; Elsohly, M.A.; Boeren, E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J. Nat. Prod., 1980, 43(2), 169-234.
[26]
Izzo, A.A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R. Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci., 2009, 30(10), 515-527.
[27]
Hazekamp, A. Cannabis; extracting the medicine.. PhD Thesis, University of Leiden: Leiden, September, 2007.
[28]
Gaoni, Y.; Mechoulam, R. The structure and synthesis of cannabigerol, a new hashish constituent. Proc. Chem. Soc., 1964, 82.
[29]
Fellermeier, M.; Zenk, M.H. Prenylation of olivetolate by a hemp transferase yelds cannabigerolic acid, the precursor of tetrahydrocannabinol. FEBS Lett, Amsterdam, 1998, 427(2), 283-285.
[30]
Packard, M.E.; Arnold, J.T. A fine structure in nuclear induction signals from ethyl alcohol. Phys. Rev., 1951, 83, 210-211.
[31]
Potter, D.J. Growth and morphology of medicinal cannabis. In: Medicinal Uses of Cannabis and Cannabinoids; Guy, G.W.; Whittle, B.A.; Robson, P., Eds.; Pharmaceutical Press: London, 2004; Vol. 1, pp. 17-54.
[32]
Potter, D.J. (2009). The propagation, characterisation and optimisation of Cannabis sativa L. as a phytopharmaceutical. . PhD Thesis, King’s College, London, May, 2009.
[33]
Fischedick, J.T.; Hazekamp, A.; Erkelens, T.; Choi, Y.H.; Verpoorte, R. Metabolomic fingerprint of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry, 2010, 71(17-18), 2058-2073.
[34]
Pauli, A.; Schilcher, H. In vitro antimicrobial activities of essential oils monographed in the European Pharmacopoeia 6th Edition. In: Handbook of Essential Oils: Science, Technology, and Applications; 1st ed.; Baser, K.H.C.; Buchbauer, G. Eds.; CRC Press: Boca Raton, 2010; pp. 353-548.
[36]
Buchbauer, G. Biological activities of essential oils. In: Handbook of Essential Oils: Science, Technology, and Applications; 1st ed.; Baser, K.H.C.; Buchbauer, G. Ed.; CRC Press: Boca Raton,, 2010; pp. 235-280.
[37]
Lee, E.R.; Kang, G.H.; Cho, S.G. Effect of flavonoids on human health: old subjects but new challenges. Recent Pat. Biotechnol., 2007, 1(2), 139-150.
[38]
McNaught, A.D.; Wilkinson, A. IUPAC. IUPAC Compendium of Chemical Terminology, 2nd ed. (The “Gold Book”); Blackwell Scientific: Oxford, 1997.
[39]
Clark, R.C.; Bohm, B.A. Flavonoid variation in Cannabis. Bot. J. Linnean . Soc., 1979, 79(3), 249-257.
[40]
Vanhoenacker, G.; Van Rompaey, P.; De Keukeleire, D.; Sandra, P. Chemotaxonomic features associated with flavonoids of cannabinoid-free cannabis (Cannabis sativa subsp. sativa L.) in relation to hops (Humulus lupulus L.). Nat. Prod. Lett., 2002, 16(1), 57-63.
[41]
ElSohly, M.A.; Slade, D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci., 2005, 78(5), 539-548.
[42]
Ross, S.A.; ElSohly, M.A.; Sultana, G.N.N.; Mehmedic, Z.; Hossain, C.F.; Chandra, S. Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L. Phytochem. Anal., 2005, 16(1), 45-48.
[43]
McPartland, J.M.; Mediavilla, V. Noncannabinoid components. In: Cannabis and Cannabinoids - Pharmacology, Toxicology, and Therapeutic Potential; Grotenhermen, F., and; Russo, E., Eds.; Haworth Press: New York, 2002; pp. 401-409.
[44]
Barrett, M.L.; Gordon, D.; Evans, F.J. Isolation from Cannabis sativa L. of cannflavin - a novel inhibitor of prostaglandin production. Biochem. Pharmacol., 1985, 34(11), 2019-2024.
[45]
Barrett, M.L.; Scutt, A.M.; Evans, F.J. Cannflavin A and B, prenylated flavones from Cannabis sativa L. Experientia, 1986, 42(4), 452-453.
[46]
Crombie, L.; Crombie, W.M.L.; Jamieson, S.V. Extractives of thailand cannabis: synthesis of canniprene and isolation of new geranylated and prenylated chrysoeriols. Tetrahedron Lett., 1980, 21(37), 3607-3610.
[47]
Radwan, M.M.; ElSohly, M.A.; Slade, D.; Ahmed, S.A.; Wilson, L.; El-Alfy, A.T.; Khan, I.A.; Ross, S.A. Non-cannabinoid constituents from a high potency Cannabis sativa variety. Phytochemistry, 2008, 69(14), 2627-2633.
[48]
Russo, E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol., 2011, 163(7), 1344-1364.
[49]
Baker, D.; Pryce, G.; Croxford, J.L.; Brown, P.; Pertwee, R.G.; Huffman, J.W.; Layward, L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 2000, 404(6773), 84-87.
[50]
Williamson, E.M. Synergy and other interactions in phytomedicines. Phytomedicine, 2001, 8(5), 400-409.
[51]
Wagner, H.; Ulrich-Merzenich, G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine, 2009, 16(2-3), 97-110.
[52]
Perry, N.S.; Houghton, P.J.; Theobald, A.; Jenner, P.; Perry, E.K. (2000). In-vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J. Pharm. Pharmacol., 2000, 52(7), 895-902.
[53]
Shoyama, Y.; Yagi, M.; Nishioka, I.; Yamauchi, T. Biosynthesis of cannabinoid acids. Phytochemistry, 1975, 14(10), 2189-2192.
[54]
Veress, T.; Szanto, J.I.; Leisztner, L. Determination of cannabinoid acids by high-performance liquid chromatography of their neutral derivatives formed by thermal decarboxylation in an open reactor. J. Chromatogr. A, 1990, 520, 339-347.
[55]
Verhoeckx, K.C.; Korthout, H.A.; van Meeteren-Kreikamp, A.P.; Ehlert, K.A.; Wang, M.; van der Greef, J.; Rodenburg, R.J.; Witkamp, R.F. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int. Immunopharmacol., 2006, 6(4), 656-665.
[56]
Romano, L.L.; Hazekamp, A. Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids, 2013, 1(1), 1-11.
[57]
Fischedick, J.T.; Glas, R.; Hazekamp, A.; Verpoorte, R. A qualitative and quantitative HPTLC densitometry method for the analysis of cannabinoids in Cannabis sativa L. Phytochem. Anal., 2009, 20(5), 421-426.
[58]
Perrotin-Brunel, H.; Buijs, W.; van Spronsen, J.; van Roosmalen, M.J.E.; Peters, C.J.; Verpoorte, R.; Witkamp, G. Decarboxylation of Δ9-tetrahydrocannabinol: Kinetics and molecular modeling. J. Mol. Struct., 2011, 987(1-3), 67-73.
[59]
Wang, M.; Wang, Y.; Avula, B.; Radwan, M.M.; Wanas, A.S.; van Antwerp, J.; Parcher, J.F.; ElSohly, M.A.; Khan, I.A. Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry. Cannabis Cannabinoid Res., 2016, 1(1), 262-271.
[60]
Gerard, K.A.; Roberts, J.S. Microwave heating of apple mash to improve juice yield and quality. Food Sci Technol, 2004, 37(5), 551-557.
[61]
Chandrasekara, N.; Shahidi, F. Effect of roasting on phenolic content and antioxidant activities of whole cashew nuts, kernels, and testa. J. Agric. Food Chem., 2011, 59(9), 5006-5014.
[62]
Viña, S.Z.; Chaves, A.R. Effect of heat treatment and refrigerated storage on antioxidant properties of pre-cut celery (Apium graveolens L.). Int. J. Food Sci. Technol., 2008, 43(1), 44-51.
[63]
Zhang, M.; Chen, H.; Li, J.; Pei, Y.; Liang, Y. Antioxidant properties of tartary buckwheat extracts as affected by different thermal processing methods. LWT-Food Sci Technol., 2010, 43(1), 181-185.
[64]
Huang, Y.; Chang, Y.; Shao, Y. Effects of genotype and treatment on the antioxidant activity of sweet potato in Taiwan. Food Chem., 2006, 98(3), 529-538.
[65]
Sharma, P.; Gujral, H.S. Effect of sand roasting and microwave cooking on antioxidant activity of barley. Food Res. Int., 2011, 44(1), 235-240.
[66]
Choi, Y.; Lee, S.M.; Chun, J.; Lee, H.B.; Lee, J. (2006). Influence of heat treatment on antioxidant activities and polyphenolic compounds of Shiitake (Lentinus edodes) mushroom. Food Chemistry., 2006, 99(2), 381-387.
[67]
De Jong, F.A.; Engels, F.E.; Sparreboom, A.; Loos, W.J.; De Bruijn, P.; Friberg, L.E.; Mathot, R.A.; Verweij, J.; Mathijssen, R.H. Influence of medicinal cannabis (MC) on the pharmacokinetics (PK) of docetaxel (DOC) and irinotecan (CPT-11). In: AACR Meeting Abstracts In: Proceedings of the 96th Annual Meeting; Bonita Springs, Florida, USA, November 30-December 4, 2005; American Association for Cancer Research: Philadelphia, USA,, 2005; pp. 938-939.
[68]
Rubin, V.; Comitas, L. (1975). Psychological assessment. In: Ganja in Jamaica, a medical anthropological study of chronic marihuana use; Rubin, V., &; Comitas, L., Eds.; Mouton Publishers: The Hague, 1975; Vol. 26, pp. 111-119.
[69]
Steinagle, G.C.; Upfal, M. Concentration of marijuana metabolites in the urine after ingestion of hemp seed tea. J. Occup. Environ. Med., 1999, 41(6), 510-513.
[70]
Hazekamp, A.; Bastola, K.; Rashidi, H.; Bender, J.; Verpoorte, R. Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J. Ethnopharmacol., 2007, 113(1), 85-90.
[71]
OMC, Office of Medicinal Cannabis, The Netherlands (2006).Official website:. www.cannabisbureau.nl (Accessed November 27, 2016).
[72]
Garrett, E.R.; Hunt, C.A. Physicochemical properties, solubility, and protein binding of Δ9-tetrahydrocannabinol. J. Pharm. Sci., 1974, 63(7), 1056-1064.
[73]
Hazekamp, A.; Verpoorte, R. Structure elucidation of the tetrahydrocannabinol complex with randomly methylated beta-cyclodextrin. Eur. J. Pharm. Sci., 2006, 29(5), 340-347.
[74]
Simpson, R. 2008 Documentary film: Run from the cure. Available from: http://www.youtube.com/watch?v=0psJhQHk_GI (Accessed October 12, 2012).
[75]
Rick , Simpson. 2013. Wernard Bruining. Mediwiet [Medi-weed] official website: http:// phoenixtears.ca/ (Accessed October 12, 2012).
[76]
Bruining, W. 2013. Wernard Bruining. Mediwiet [Medi-weed] official website:. http://www.mediwiet.nl (Accessed October 12, 2012)
[77]
Naphtha, M.S.D.S. https://www.collectioncare.org/MSDS/naphthamsds.pdf (Accessed November 24, 2012).
[78]
Dr. Diane. 2013. Youtube instruction video: http://www.youtube. com/watch?v=vs66uyiH968 (Accessed October 12, 2012)
[79]
Hazekamp, A.; Choi, Y.H.; Verpoorte, R. Quantitative analysis of cannabinoids from Cannabis sativa using 1H-NMR. Chem. Pharm. Bull., 2004, 52(6), 718-721.
[80]
McPartland, J.M.; Russo, E.B. Cannabis is more than simply Δ9-tetrahydrocannabinol. Psychopharmacology., 2003, 165(4), 431-432.
[81]
Russo, E.B.; McPartland, J.M. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther, 2001, 1(3/4), 103-132.
[82]
NIST. National Institute of Standards and Technology, https://www.nist.gov/ (Accessed October 17, 2017).
[83]
Fairbairn, J.W.; Liebmann, J.A. The extraction and estimation of the cannabinoids in Cannabis sativa L. and its products. J. Pharm. Pharmacol., 1973, 25(2), 150-155.
[84]
Schauer, G.L.; King, B.A.; Bunnell, R.E.; Promoff, G.; McAfee, T.A. Toking, vaping, and eating for health or fun: marijuana use patterns in adults, U.S., 2014. Am. J. Prev. Med., 2016, 50(1), 1-8.
[85]
Varlet, V.; Concha-Lozano, N.; Berthet, A.; Plateel, G.; Favrat, B.; De Cesare, M.; Lauer, E.; Augsburger, M.; Thomas, A.; Giroud, C. Drug vaping applied to cannabis: Is “Cannavaping” a therapeutic alternative to marijuana? Sci. Rep., 2016, 6, Article number: 25599.
[86]
Whittle, B.; Hill, C.A.; Flockhart, I.R.; Dows, D.V.; Gibson, P.; Wheatley, G.W. Extraction of pharmaceutically active components from plant materials. U.S. Patent 7,344,736 B2, March 18 2008.
[87]
FDA, U.S. Food & Drug Administration, 2016 Warning Letters and Test Results for Cannabidiol-Related Products. http://www. fda.gov/NewsEvents/PublicHealthFocus/ucm484109.htm (Accessed December 12, 2016).
[88]
Hazekamp, A.; Epifanova, S. Grote variatie in samenstelling cannabisolie noopt tot regels. Pharm. Weekbl., 2017, 152(44), 16-18.
[89]
Vandrey, R.; Raber, J.C.; Raber, M.E.; Douglass, B.; Miller, C.; Bonn-Miller, M.O. (2015). Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA, 2015, 313(24), 2491-2493.
[90]
Grinspoon, L.; Bakalar, J.B. Marihuana, the forbidden medicine, Revised ed.; Yale University Press: New Haven, 1997.
[91]
Huber, G.; First, M.; Grubner, O. Marijuana and tobacco smoke gas-phase cytotoxins. Pharmacol. Biochem. Behav., 1991, 40(3), 629-636.
[92]
Institute of Medicine. 1982. Marijuana and Health; National Academy Press: Washington, District of Columbia, USA, 1982.
[93]
Gieringer, D.H. Marijuana water pipe and vaporizer study. MAPS Bull 1996, 6(3), 59-66 Multidisciplinary Association for Psychedelic Studies. Reference: Available from:.www.maps.org/news-letters/v06n3/06359mj1.html
[94]
Chemic Laboratories. Proof of concept: Release of chemical constituents in cannabis sativa at 170-1858C versus combustion. Unpublished report to California NORML and MAPS, Nov 17th,. 2000.
[95]
Gieringer, D.H. Cannabis “vaporization”: A promising strategy for smoke harm reduction. J Cannabis Ther, 2001, 1(3/4), 153-170.
[96]
Gieringer, D.H.; StLaurent, J.; Goodrich, S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther, 2004, 4(1), 7-27.
[97]
Storz & Bickel, Tuttlingen, Germany. https://www.storz-bickel.com/eu/en/volcano/ (Accessed January 2018).
[98]
Hazekamp, A.; Ruhaak, R.; Zuurman, L.; Van Gerven, J.; Verpoorte, R. Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol. J. Pharm. Sci., 2006, 95(6), 1308-1317.
[99]
Abrams, D.I.; Vizoso, H.P.; Shade, S.B.; Jay, C.; Kelly, M.E.; Benowitz, N.L. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin. Pharmacol. Ther., 2007, 82(5), 572-578.
[100]
CBD vape e-liquid (THC ≤ 0.2%) https://sensiseeds.com/en/cbd-products/cbd-e-liquid-sativa (Accessed January 2, 2018).
[102]
Giroud, C.; de Cesare, M.; Berthet, A.; Varlet, V.; Concha-Lozano, N.; Favrat, B. E-cigarettes: a review of new trends in cannabis use. Int. J. Environ. Res. Public Health, 2015, 12(8), 9988-10008.
[103]
Stinchcomb, A.L.; Valiveti, S.; Hammell, D.C.; Ramsey, D.R. Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. J. Pharm. Pharmacol., 2004, 56(3), 291-297.
[104]
Challapalli, P.V.; Stinchcomb, A.L. In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int. J. Pharm., 2002, 241(2), 329-339.
[105]
Lodzkia, M.; Godina, B.; Rakoua, L.; Mechoulam, R.; Gallily, R.; Touitou, E. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J. Control. Release, 2003, 93(3), 377-387.
[106]
Paudel, K.S.; Hammell, D.C.; Agu, R.U.; Valiveti, S.; Stinchcomb, A.L. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev. Ind. Pharm., 2010, 36(9), 1088-1097.
[107]
Touitou, E.; Fabin, B.; Dany, S.; Almog, S. Transdermal delivery of tetrahydrocannabinol. Int. J. Pharm., 1988, 43(1-2), 9-15.
[108]
Touitou, E. Compositions for applying active substances to or through the skin. U.S. Patent 5,540,934, July 30 1996.
[109]
Valiveti, S.; Hammell, D.C.; Earles, D.C.; Stinchcomb, A.L. Transdermal delivery of the synthetic cannabinoid WIN 55,212-2: in vitro/in vivo correlation. Pharm. Res., 2004, 21(7), 1137-1145.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Drug Safety
Current Drug Targets
Current Organic Chemistry
Current Organic Synthesis
Mini-Reviews in Organic Chemistry
Letters in Organic Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Related Books
Advances in Organic Synthesis
Frontiers in Drug Design and Discovery
The Synthetic Methods, Structures, and Properties of the Ca-C σ Bond Organocalcium Containing Compounds
Advances in Organic Synthesis
Chemistry of Bipyrazoles: Synthesis and Applications
Frontiers in Cardiovascular Drug Discovery
Advances in Organic Synthesis
Advanced Nanocatalysis for Organic Synthesis and Electroanalysis
Frontiers in Drug Design and Discovery
Advances in Organic Synthesis
Article Metrics
45
4
1
1